Terms: = Prostate cancer AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874 AND Prognosis
14 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Genomic characterization of idh-mutant astrocytoma progression to grade 4 in the treatment setting.
Rautajoki KJ; Jaatinen S; Hartewig A; Tiihonen AM; Annala M; Salonen I; Valkonen M; Simola V; Vuorinen EM; Kivinen A; Rauhala MJ; Nurminen R; Maass KK; Lahtela SL; Jukkola A; Yli-Harja O; Helén P; Pajtler KW; Ruusuvuori P; Haapasalo J; Zhang W; Haapasalo H; Nykter M
Acta Neuropathol Commun; 2023 Nov; 11(1):176. PubMed ID: 37932833
[TBL] [Abstract] [Full Text] [Related]
3. 68 Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters.
Verma P; Singh BK; Sudhan MD; Singh RK; Bagul SD; Chandak AR; Soni BK; Shelly D; Basu S
Clin Nucl Med; 2023 Dec; 48(12):e559-e563. PubMed ID: 37883060
[TBL] [Abstract] [Full Text] [Related]
4. Determination of TMPRSS2-ERG, SPOP, FOXA1, and idh1 prostate cancer molecular subtypes in Colombian patients and their possible implications for prognosis.
Montero-Ovalle W; Sanabria-Salas MC; Mesa-López de Mesa J; Varela-Ramírez R; Segura-Moreno YY; Sánchez-Villalobos SA; Nuñez-Lemus M; Serrano ML
Cell Biol Int; 2023 May; 47(5):1017-1030. PubMed ID: 36740223
[TBL] [Abstract] [Full Text] [Related]
5. PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas.
Rautajoki KJ; Jaatinen S; Tiihonen AM; Annala M; Vuorinen EM; Kivinen A; Rauhala MJ; Maass KK; Pajtler KW; Yli-Harja O; Helén P; Haapasalo J; Haapasalo H; Zhang W; Nykter M
Sci Rep; 2022 Aug; 12(1):14083. PubMed ID: 35982066
[TBL] [Abstract] [Full Text] [Related]
6. Analysis and Validation of Key Genes Related to Radiosensitivity in prostate cancer.
Huang W; Xu Y
Urol J; 2022 Dec; 20(1):22-28. PubMed ID: 35466393
[TBL] [Abstract] [Full Text] [Related]
7. Comprehensive landscape of STEAP family functions and prognostic prediction value in glioblastoma.
Chen H; Xu C; Yu Q; Zhong C; Peng Y; Chen J; Chen G
J Cell Physiol; 2021 Apr; 236(4):2988-3000. PubMed ID: 32964440
[TBL] [Abstract] [Full Text] [Related]
8. Molecular Subtypes of prostate cancer.
Arora K; Barbieri CE
Curr Oncol Rep; 2018 Jun; 20(8):58. PubMed ID: 29858674
[TBL] [Abstract] [Full Text] [Related]
9. Six-Transmembrane Epithelial Antigen of prostate 3 Predicts Poor prognosis and Promotes Glioblastoma Growth and Invasion.
Han M; Xu R; Wang S; Yang N; Ni S; Zhang Q; Xu Y; Zhang X; Zhang C; Wei Y; Ji J; Huang B; Zhang D; Chen A; Li W; Bjerkvig R; Li X; Wang J
Neoplasia; 2018 Jun; 20(6):543-554. PubMed ID: 29730475
[TBL] [Abstract] [Full Text] [Related]
10. cancer/Testis Antigens: "Smart" Biomarkers for Diagnosis and prognosis of prostate and Other cancers.
Kulkarni P; Uversky VN
Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28362316
[TBL] [Abstract] [Full Text] [Related]
11. The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant idh1 and kills glioma stem cells.
Liu Y; Gilbert MR; Kyprianou N; Rangnekar VM; Horbinski C
Acta Neuropathol; 2014 Nov; 128(5):723-32. PubMed ID: 25135281
[TBL] [Abstract] [Full Text] [Related]
12. The CpG island methylator phenotype: what's in a name?
Hughes LA; Melotte V; de Schrijver J; de Maat M; Smit VT; Bovée JV; French PJ; van den Brandt PA; Schouten LJ; de Meyer T; van Criekinge W; Ahuja N; Herman JG; Weijenberg MP; van Engeland M
Cancer Res; 2013 Oct; 73(19):5858-68. PubMed ID: 23801749
[TBL] [Abstract] [Full Text] [Related]
13. Immunohistochemical demonstration of isocitrate dehydrogenase 1 (idh1) mutation in a small subset of prostatic carcinomas.
Mauzo SH; Lee M; Petros J; Hunter S; Chang CM; Shu HK; Bellail AC; Hao C; Cohen C
Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):284-7. PubMed ID: 23235339
[TBL] [Abstract] [Full Text] [Related]
14. Nuclear karyopherin a2: a novel biomarker for infiltrative astrocytomas.
Gousias K; Becker AJ; Simon M; Niehusmann P
J Neurooncol; 2012 Sep; 109(3):545-53. PubMed ID: 22772608
[TBL] [Abstract] [Full Text] [Related]
